Potential Therapeutic Strategies for Steatosis, Oxidative Stress, Inflammation, and Fibrosis in Liver Disease - PubMed
7 hours ago
- #therapeutic strategies
- #liver disease
- #fibrosis treatment
- Ursodeoxycholic acid (UDCA) is FDA-approved for primary biliary cholangitis and also protects against steatohepatitis, fibrosis, and drug-induced liver injury through antioxidant, anti-inflammatory, and anti-apoptotic actions.
- Pirfenidone, known for treating idiopathic pulmonary fibrosis, reduces liver fibrosis by anti-inflammatory and antioxidant effects, including inhibition of inflammasome signaling and upregulation of Nrf2 pathway.
- S-adenosyl-L-methionine (SAM) acts as a methyl donor, increases glutathione levels for antioxidant effects, helps prevent fibrosis, and may attenuate hepatocellular carcinoma development.
- N-acetylcysteine (NAC) is a precursor to glutathione and is used for drug-induced liver injury and chronic liver conditions, offering antioxidant and anti-inflammatory benefits.
- These compounds—UDCA, pirfenidone, SAM, and NAC—represent potential therapeutic strategies targeting steatosis, oxidative stress, inflammation, and fibrosis in liver disease.